Tesamorelin acetate bulk supplier for pharma manufacturers

Tesamorelin Acetate 1mg, 2mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 1mg, 2mg

Reference Brands: Egrifta (USA)

Tesamorelin is a growth hormone-releasing factor analogue that reduces excess abdominal fat in people with HIV-associated lipodystrophy. It is injected daily under the skin and is made by Theratechnologies as Egrifta. It is still a patented innovator product. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit | 3 enquiries in the last 90 days

Manufacture or export Tesamorelin Acetate? List it or send an offer →

Product Description:

Tesamorelin is a synthetic analogue of growth hormone-releasing factor, stabilised against rapid breakdown. It does not supply growth hormone; it prompts the pituitary to release its own, in the body's natural pulsatile pattern, which preserves the feedback loops that are lost when growth hormone itself is injected. The target is visceral adipose tissue — the metabolically active fat around the abdominal organs, which is particularly sensitive to growth hormone's lipolytic effect.

It is licensed for one specific problem: the excess visceral abdominal fat that develops in people with HIV-associated lipodystrophy, a disfiguring and metabolically harmful body-shape change linked to long-term antiretroviral therapy. It reduces visceral fat while largely sparing subcutaneous fat, and the effect reverses if treatment stops. Injection site reactions, arthralgia, oedema and raised blood glucose occur; glucose tolerance requires monitoring, and it is contraindicated in active malignancy and pregnancy.

Sourcing notes. Originator product, on patent, with approval largely confined to the United States — confirm registration per destination. It is worth being explicit with buyers that this is not a general weight-loss treatment and is not licensed as one. Supplied as powder for reconstitution; cold chain requirements differ between presentations, so confirm which.

How Tesamorelin Acetate is supplied today, and licensing ahead of patent expiry

Tesamorelin Acetate is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Tesamorelin Acetate, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Tesamorelin Acetate supply →

Back to Listing

Frequently Asked Questions

Adults with HIV and excess abdominal fat (lipodystrophy). It reduces visceral fat while treatment continues.

Egrifta SV (2 mg vial) and Egrifta WR, made by Theratechnologies. There is no generic.

Through named-patient or special import routes, since it is not registered in most countries.

Egrifta (Tesamorelin) is developed and sold by Theratechnologies. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.